$12.270
+0.521 (+4.25%)收盤時
FENC 資訊
FENC 事件
Fennec Pharmaceuticals Q2 Revenue Reaches $17.87M
Reports Q2 revenue $17.87M, consensus $16.12M. "Our second quarter reflects another period of strong execution across the business, highlighted by our seventh consecutive quarter of growth. We continue to build momentum by investing in the evidence that will shape the future of PEDMARK, with important data presented at ASCO and a growing pipeline of investigator-sponsored studies that we believe will further expand our understanding of its potential," said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. "As evidenced in our record EBITDA generation in the second quarter, we have a highly effective business model that is primed to optimize our anticipated growth while advancing our mission to improve outcomes for patients."
Fennec Pharmaceuticals Q1 Revenue $15.1M Beats Expectations
Reports Q1 revenue $15.1M, consensus $13.84M. "We are encouraged by our continued quarter-over-quarter growth and strong start to the year. 2026 is a defining period for Fennec, with growing clinical interest in independently evaluating PEDMARK across new patient populations and tumor types that reinforces our confidence in its broader potential," said Jeff Hackman, CEO of Fennec Pharmaceuticals. "At the same time, the strategic enhancements we've made to our field force are already sharpening our execution and expanding our reach - in tandem, the positive experiences we're seeing through our Fennec HEARS program are translating into meaningful access and strong conversion rates, resulting in more patients being treated. Coupled with our solid financial foundation, we believe we are well-positioned to continue to build momentum and deliver sustained growth throughout 2026."
Fennec Pharmaceuticals Reports Q4 Revenue of $13.78M
Reports Q4 revenue $13.78M, consensus $14.73M. "Our 2025 results validate that our strategy is clear and the foundation we built over the past year is now propelling Fennec into its next chapter of growth. We delivered record net product sales, achieved significant growth within our Fennec Hears program, and advanced independent clinical evidence generation for Pedmark - all while driving quarter-over-quarter growth in every quarter in 2025. These results demonstrate increasing Pedmark adoption across key accounts and patient segments, effective field execution, and sustained progress across the organization," said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. "Concurrently, we strengthened our financial position through prudent operating decisions and strategic financial initiatives, including the closing of public and private offerings and the completion of full debt redemption."
Fennec Pharmaceuticals Settles Litigation with Cipla
Fennec Pharmaceuticals announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them regarding Cipla's application to FDA for approval to market a generic version of Fennec's PEDMARK product. Under the terms of the agreement, the lawsuit will be dismissed with each party bearing their own costs, and Cipla will not enter the market with its generic sodium thiosulfate product until September 1, 2033, or earlier under certain circumstances.
Fennec Pharmaceuticals Initiates Study on Sodium Thiosulfate Injection
Fennec Pharmaceuticals announced that the Tampa General Hospital Cancer Institute is initiating a study evaluating the real-world clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in Adolescent and Young Adult and adult cancer patients receiving cisplatin-based treatment. "Real-world evidence plays a critical role in demonstrating the clinical utility of PEDMARK across diverse patient populations and tumor types," said Pierre Sayad, PhD, M.S., chief medical officer of Fennec Pharmaceuticals. "As more institutions generate data on its use outside of controlled trials, clinicians will gain a clearer picture of the important role of PEDMARK in providing hearing loss protection for patients receiving cisplatin."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。